Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 34, Issue 7, Pages 1193-1200Publisher
WILEY
DOI: 10.1111/jgh.14532
Keywords
daikenchuto (DKT); ginsenoside Rb1; intestinal mucosal healing
Categories
Funding
- Japan Society for the Promotion of Science [16K09322, 18K06224, 16H05289]
- R&D Matching Funds in the Field for Knowledge Integration and Innovation by the National Agriculture and Food Research Organization
- Grants-in-Aid for Scientific Research [16K09322, 18K06224] Funding Source: KAKEN
Ask authors/readers for more resources
Background and Aim Daikenchuto, a traditional Japanese herbal medicine, has been reported to exhibit anti-inflammatory effects against intestinal inflammation. However, whether daikenchuto has a therapeutic effect against intestinal mucosal injuries remains unclear. Thus, the aim of this study was to determine the effect of daikenchuto on intestinal mucosal healing. Methods Colitis was induced in male Wistar rats by using trinitrobenzenesulfonic acid. Daikenchuto (900 mg/kg/day) was administered for 7 days after the induction of colitis. Thereafter, intestinal mucosal injuries were evaluated by determining the colonic epithelial regeneration ratio ([area of epithelial regeneration/area of ulcer] x 100). Restoration of rat intestinal epithelial cells treated with daikenchuto and its constituent herbs (Zanthoxylum fruit, processed ginger, and ginseng) and ginsenoside Rb1, which is a ginseng ingredient, was evaluated using a wound-healing assay. Results The colon epithelial regeneration ratio in the daikenchuto-treated rats was significantly higher than that in the control rats. Daikenchuto, ginseng, and ginsenoside Rb1 enhanced wound healing, and the ginsenoside Rb1-induced enhancement was inhibited by extracellular signal-regulated kinase and Rho inhibitors. Conclusions Daikenchuto and its constituent, ginsenoside Rb1, promoted wound healing. Because mucosal healing is one of the most important therapeutic targets in patients with inflammatory bowel disease, ginsenoside Rb1 may be a novel therapeutic agent against intestinal mucosal damage such as that occurring in intestinal bowel disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available